Boston Scientific Corp (BSX)

[yellolab]

Belo sun set to do big things in gold
Drawing attention from big names agnico puts bets on quality properties.
Low cost oz, mining friendly Brazil

[catty]

conix: thanks for your post. It's interesting how our little stock keeps inches up every day. Wonder if they'll ever eliminate the medical equipment tax. This is also a good take over target

[conix]

Driving Shareholder Value

Following strong financial results in 2014 and the first quarter of 2015, the company is targeting at- or above-market operational revenue growth, and consistent double-digit adjusted EPS growth (excluding the negative impact of foreign currency) through ongoing operating margin improvement initiatives, and a differentiated five-year growth strategy aims for 25 percent adjusted operating margins by 2017.

In addition, the company will highlight its goal of increasing adjusted operating margins by an additional 50 to 100 basis points annually in 2018 and 2019.

[catty]

It's the only thing green on my radar today.

[catty]

conix: very healthy chart. Pardon the pun

[conix]

Another Chart

[conix]

Boston Scientific PT Raised to $20.00 at RBC Capital (BSX)

Posted on April 21, 2015 by John Miller in Analyst Articles - US, Investing


Boston Scientific logoAnalysts at RBC Capital raised their target price on shares of Boston Scientific (NYSE:BSX) from $17.00 to $20.00 in a research report issued to clients and investors on Monday. The firm currently has an “outperform” rating on the stock. RBC Capital’s price objective indicates a potential upside of 9.95% from the company’s current price.

A number of other analysts have also recently weighed in on BSX. Analysts at Argus reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, March 30th. Analysts at Barclays raised their price target on shares of Boston Scientific from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Monday, March 23rd. Analysts at Raymond James initiated coverage on shares of Boston Scientific in a research note on Friday, March 20th. They set an “outperform” rating and a $21.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating and set a $17.00 price target on shares of Boston Scientific in a research note on Thursday, March 19th. Ten equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Boston Scientific presently has an average rating of “Buy” and a consensus target price of $17.70.

Boston Scientific (NYSE:BSX) opened at 18.19 on Monday. Boston Scientific has a 52-week low of $11.10 and a 52-week high of $18.43. The stock has a 50-day moving average of $17. and a 200-day moving average of $14.. The company’s market cap is $24.20 billion.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.22 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.21 by $0.01. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.91 billion. During the same quarter last year, the company posted $0.21 earnings per share. Boston Scientific’s revenue was up 2.7% compared to the same quarter last year. Analysts expect that Boston Scientific will post $0.91 EPS for the current fiscal year.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women’s Health, Neuromodulation, and Electrophysiology.

[conix]

Significant Revenue Gains In Store For Boston Scientific

Summary

•Boston Scientific receives approval from the Food and Drug Administration (FDA) to market its Watchman Heart Device in the US.

•The global atrial fibrillation market is expected to grow to $16 billion by 2020 while the Watchman Heart Device is expected to bring in $500 million in additional annual revenues.

•BSX agreed to buy the American Medical Systems' urology portfolio from Endo International Plc for approximately $1.6 billion.

•The newly acquired portfolio generated $400 million in sales and an operating income of $130 million in 2014 and should assist the company's Urology and Women's Health division.

•BSX shares hover at $17.62 per share, but show strong potential over coming year as new access to the US market for Watchman devices can prove to be a game changer.



Boston Scientific (NYSE:BSX), the Marlborough, Massachusetts-based medical devices manufacturer, has at long last received approval from the Food and Drug Administration (FDA) to market its Watchman Heart Device in the US. The revelation was well received by Wall Street as the stock climbed by more than $1 per share over the past week since the news hit the markets. So the question remains on how important this approval is for the Massachusetts-based medical equipment developer?

The Watchman Heart Device is a device that is implanted on the left atrial appendage of the heart and helps prevent blood clots. Atrial fibrillation devices, such as the Watchman device, are often used as substitutes for anticoagulants by those patients who cannot use standard drugs like warfarin due to its side effects or a refusal to use them altogether. When it comes to market potential for the device, the global market is expected to continue to grow at an annual compounded rate of 13% and should reach a total size of more than $16 billion in terms of revenues. The growth is primarily going to be lead by the rising number of geriatric patients prevalent in the market. In the US alone, around 3 million patients suffer from atrial fibrillation, and the number is expected to cross the 10 million mark by 2050.

Up till now, Watchman Heart Devices were widely available across other countries besides the US since 2005, having been denied by the FDA over the years due to its efficacy and complexity when it comes to installing the device. The device lies under the Cardiac Rhythm Management (CRM) division of Boston Scientific and is expected to increase annual revenues by $500 million. Currently, CRM makes up about 26% of total sales for the company, and an additional $500 million annually (which should grow with time) will make the segment contribute about 30% of the company's total revenue. Moreover, the FDA approval will act as a small reputation boost for its market overseas where the new approval can be used as a marketing strategy to gain more traction. This approval will bring in much needed growth in the CRM division, which has remained flat over the year only experiencing a meager 1% growth over the past year.

However, it won't exactly be smooth sailing for Boston Scientific's Watchman. First of all, the FDA's approval was accompanied with a report that still said that the device lacked efficacy as compared to its pharmacological substitute, thereby insinuating that it should only be used as an alternative for those patients to whom warfarin does not suit well or those who refuse to take the drug. Moreover, there are a variety of anti-coagulants available in the market, and the device is bound to face some decent resistance despite its new approval.

In other positive news for the company, earlier this month, Boston Scientific agreed to buy the American Medical Systems' urology portfolio from Endo International Plc for approximately $1.6 billion. The purchase is expected to assist the company in strengthening its Urology and Women's Health division, which boasts an annual turnover of $535 million. The newly acquired portfolio generated $400 million in sales and an operating income of $130 million in 2014.

More recently, the company also announced the approval of its EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) system by the FDA and CE (European Conformity). The device, which provides protection for patients at risk of sudden cardiac arrest, has been introduced to limited markets in Europe with a more comprehensive launch planned for the third quarter of 2015.

As far as the company stock goes, many analysts have revised their ratings of the stock since it announced its earnings on 4th February. The company had revenues of $1.89 billion for the quarter as compared to the consensus estimate of $1.91 billion, but managed to beat analysts' expectations by posting earnings per share of $0.22 for the quarter as compared to the consensus estimate of $0.21. This resulted in analysts at BMO Capital Markets and Credit Suisse revising their price target on Boston Scientific shares from $18 per share to $19 per share, giving the company a rating of "outperform".

Currently, the stock is trading at $17.62 per share, having gone up by more than 30% over the year. Given that the company now has access to the US market for its lucrative Watchman Device, we can expect an annual boost of $500 million over the next couple of years even if this number does not grow. There will be a lot riding on this device and will potentially face headwinds from alternatives such as warfarin since the device has yet to prove superiority over the drug. Along with the new acquisition of the urology portfolio from Endo International, we can expect some significant revenue gains for the company this year.

[conix]

BSX Chart

[conix]

The Holy Grail--Insurance Reimbursement

"Currently, the S-ICD System is covered nationally by Medicare, Aetna, Cigna and others, and regionally by numerous private and Medicaid plans, providing coverage for approximately 170 million individuals in the U.S."

[pkdaddy64]

I am looking for a push back over $18.00 Today with or without the markets being up.

[catty]

marchio: I even like it on its own

[marchio]

just a gut feeling... thats all

[catty]

oxnous: that would also be very nice.

[catty]

marchio: A J&J take over would be very nice. However, what makes u think so?

[pkdaddy64]

We should begin to move higher Today.

[bd2004]

Big news.

[marchio]

would never happen. Goverment would never approve it.

[oxnous]

St. Judes Medical is another medical device company that may be interested in BSX.

[marchio]

what about them?

[oxnous]

What about St. Jude Medical?

[marchio]

J & J will buy BSX

[conix]

Pain management medical devices are in high demand. The key is to have insurance reimbursement. BSX has it, Another, CTTC, does not yet.

I own both


CTTC is rumored to have news on a Federal Contract TBA soon. (Feds do not need to have insurance reimbursement because they are "self insured".)





BSX--should benefit from repeal of medical device tax in ObamaCare.

[stocktrademan]

$BSX DD Notes ~ http://www.ddnotesmaker.com/BSX

bullish
quick trade

bullish price objective 32.5
double bottom off of long term support


$BSX recent news/filings

## source: finance.yahoo.com

Tue, 23 Dec 2014 13:08:34 GMT ~ Omega Advisors eliminates position in Boston Scientific


read full: http://finance.yahoo.com/news/omega-advisors-eliminates-position-boston-130834183.html
*********************************************************

Mon, 22 Dec 2014 22:45:00 GMT ~ IPO Stock Watch: Medical Device Maker Nevro Hits High


read full: http://news.investors.com/122214-731688-recent-ipo-nevro-hits-high-after-upgrade.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************

Mon, 22 Dec 2014 13:47:48 GMT ~ Boston Scientific To Participate In 33rd Annual J.P. Morgan Healthcare Conference

[at noodls] - Dec 22, 2014 MARLBOROUGH, Mass. , Dec. 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January ...

read full: http://www.noodls.com/view/FFC1EEBEAEFA6B09D3F18D7CD79C6F999E774633
*********************************************************

Mon, 22 Dec 2014 13:45:00 GMT ~ Boston Scientific To Participate In 33rd Annual J.P. Morgan Healthcare Conference

[PR Newswire] - MARLBOROUGH, Mass., Dec. 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 33 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 ...

read full: http://finance.yahoo.com/news/boston-scientific-participate-33rd-annual-134500049.html
*********************************************************

Fri, 19 Dec 2014 11:47:42 GMT ~ Puts surging in Boston Scientific


read full: http://finance.yahoo.com/news/puts-surging-boston-scientific-114742428.html
*********************************************************


$BSX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$BSX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/BSX/company-info
Ticker: $BSX
OTC Market Place: Not Available
CIK code: 0000885725
Company name: Boston Scientific Corp.
Company website: http://www.bsci.com
Incorporated In: DE, USA


$BSX share structure

## source: otcmarkets.com

Market Value: $17,416,812,256 a/o Dec 24, 2014
Shares Outstanding: 1,326,489,890 a/o Oct 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$BSX extra dd links

Company name: Boston Scientific Corp.
Company website: http://www.bsci.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BSX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BSX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BSX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BSX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BSX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BSX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BSX/news - http://finance.yahoo.com/q/h?s=BSX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BSX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BSX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BSX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BSX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BSX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BSX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BSX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BSX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BSX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BSX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Boston+Scientific+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Boston+Scientific+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Boston+Scientific+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.bsci.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.bsci.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.bsci.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BSX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BSX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BSX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BSX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BSX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000885725&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BSX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BSX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BSX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BSX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BSX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BSX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BSX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BSX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BSX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BSX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BSX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BSX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BSX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BSX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BSX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BSX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BSX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BSX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BSX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BSX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BSX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BSX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BSX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BSX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BSX



$BSX DD Notes ~ http://www.ddnotesmaker.com/BSX

[BundaBoy]

Spinal Stims work but they are so expensive and subject to new technologies that are non-invasive. I'd be cautious about this one.

[catty]

I feel almost certain that Obama will eliminate the tax on medical devices. For him it would be a throw away gesture. However, I don't think anything will happen before January.

[catty]

bought on Friday even tho I don't think anything will be decided re the tax on medical equipment until January

[catty]

I'm starting to look at BSX again since the Republicans won over the Senate. There now is a good chance they will revoke the medical equipment tax.

[oxnous]

Earnings Out!

NATICK, Mass., April 29, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $1.774 billion during the first quarter ended March 31, 2014. This represents 4 percent operational revenue growth (constant currency basis, excluding divested businesses) and 1 percent revenue growth on a reported basis, all compared to the prior year period. The company also achieved adjusted earnings per share of $0.20 in the period, compared to $0.16 a year ago, and GAAP earnings per share during the period of $0.10, compared to a GAAP loss per share of $(0.26) a year ago.

"I am pleased with our overall performance in the first quarter as our team delivered accelerated EPS and consistent revenue growth," stated Mike Mahoney, president and chief executive officer, Boston Scientific Corporation. "Our international businesses performed very well in the quarter as we continued to diversify geographically. We remain confident in both our outlook for the year and in our strategy."

First quarter financial results and recent developments:

Achieved first quarter sales of $1.774 billion, representing 4 percent operational revenue growth and 1 percent revenue growth on a reported basis, all compared to the prior year period.

Delivered adjusted earnings per share of $0.20 compared to the company's guidance range of $0.16 to $0.18, and GAAP earnings of $0.10 per share compared to the company's guidance range of $0.06 to $0.08 per share.

Achieved 9 percent revenue growth in MedSurg, with Neuromodulation growing 23 percent, Urology and Women's Health growing 8 percent and Endoscopy growing 5 percent, all on a constant currency basis over the prior year period.

Improved performance in Interventional Cardiology, which experienced 1 percent revenue growth versus the prior year period on a constant currency basis.

Achieved year-over-year revenue growth internationally of 8 percent, primarily driven by 22 percent growth in Emerging Markets, which represented 9 percent of total company sales, all on a constant currency basis.

Generated operating cash flow of $198 million and used $125 million to repurchase approximately 10 million shares under the company's existing share repurchase authorization.

Announced U.S. FDA approval for the DYNAGEN™ MINI and INOGEN™ MINI ICDs, as well as the DYNAGEN™ X4 and INOGEN™ X4 CRT-Ds, which represent the latest generation of defibrillators and heart failure devices designed to advance patient care. (They should see some topline revenue growth from these new devices in this quarter's results)

Published new interim registry data (EFFORTLESS S-ICD) confirming long-term safety and effectiveness of the S-ICD™ System and the clinical benefits in a broad range of patients at risk of sudden cardiac arrest.

Announced CE Mark approval of the Ingevity™ family of MRI-compatible pacing leads and the REBEL™ Platinum Chromium Coronary Stent System, and an expanded CE Mark indication for the WallFlex™ Esophageal Stent (for the treatment of refractory benign esophageal strictures).

Reported key data at the American College of Cardiology 2014 Scientific Sessions for cardiac resynchronization therapy technology (MADIT-CRT), platinum chromium stents (PLATINUM Workhorse), and the Lotus™ Valve System (REPRISE II), thus reinforcing a commitment to the development of innovative therapies to improve care for patients with cardiovascular disease.

[oxnous]

I guess that Shingo Award has not helped too much.

[oxnous]

My bet is that BSX is bought out before the end of this year. With Obamacare, the small companies need access to capital and a diversified product mix to weather the storms in the healthcare market now.

But, if Obamacare could some how go awayNow that would be a different story.

And all small medical device companies would run up on that news. Or, at the minimum, the repeal of the medical device tax.

[oxnous]

BSX is still on a roll. Very strong chart, imo.

[oxnous]

I expect that medical device tax will be eliminated too.

Too much of a burden to innovative, yet unprofitable, companies out there working to get to profiability.

But Obama needs to acquaint hiself with economics to understand this

[catty]

Rand: Interesting thought. I'm just waiting for the govt. to eliminate the medical equipment tax.

[catty]

Rand: Interesting thought. I'm just waiting for the govt. to eliminate the medical equipment tax.

[oxnous]

The rating change is going the right way. LOL

[oxnous]

I, too, do not believe that BSX will stay independent. Long and strong.

[RandolRocketman]

I have been watching BSX for some time, since back when they bought Guidant for 26 Billion, in a bidding war with J&J.
I have been expecting J&J to simply buy up BSX, and get Guidant for free in the deal. Still might happen, now that an ex J&J VP is the new CEO?
Just sayin...

[catty]

oxnous: Ameritrde raised their rating to a HOLD

[oxnous]

Another revenue soource coming for BSX.

I would not be surprised if BSX where to get bought out by Stryker or STJM in 2014.

[catty]

ox: agreed

[oxnous]

Obamacare is going to be altered big time. And the medical device tax will be one of the targets for repealing totally.

How they thinkthat a medical device company can pay that tax without passing on that extra cost to patients is beyond me.

But it seems to be beyond the understanding of liberals.

[catty]

ox: I think the big move will come if/when they remove the tax

[oxnous]

Now they can get revenue in Europe and the US with another product.

[catty]

ox: two great minds!

[oxnous]

I am in too. Uncanny

[catty]

I'm back in.

[catty]

oxnous: I seriouslsy thinking of getting back into it. Appreciate your imput

[oxnous]

BSX's spinal implants for pain will also get a boost now that the FDA is cracking down on painkiller prescriptions too. The stars are getting in line.

[catty]

ox: agreed. I'm planning to go back in. that tax was never popular with Congress